NAT screening of blood and plasma donations: evolution of technology and regulatory policy.
Tabor
Edward
E
Office of Blood Research and Review, Food and Drug Administration, Rockville, Maryland 20852-1448, USA. tabor@cber.fda.gov
Epstein
Jay S
JS
D001769:Blood / Q000821:virology*; D001782:Blood Donors / Q000331:legislation & jurisprudence; D001803:Blood Transfusion / Q000331:legislation & jurisprudence / Q000592:standards; D004279:DNA, Viral / Q000097:blood*; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D015658:HIV Infections / Q000097:blood / Q000517:prevention & control / Q000635:transmission; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006518:Hepatitis Viruses / Q000235:genetics / Q000302:isolation & purification; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D017053:Infection Control / Q000331:legislation & jurisprudence / Q000379:methods*; D008004:Licensure; D008403:Mass Screening / Q000331:legislation & jurisprudence / Q000379:methods* / Q000592:standards; D020411:Oligonucleotide Array Sequence Analysis; D010322:Parvoviridae Infections / Q000097:blood / Q000517:prevention & control / Q000635:transmission; D016732:Parvovirus B19, Human / Q000302:isolation & purification; D010949:Plasma; D017410:Practice Guidelines as Topic; D011640:Public Policy; D012367:RNA, Viral / Q000097:blood*; D012680:Sensitivity and Specificity; D065227:Transfusion Reaction; D038301:Virus Inactivation
D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D012367:RNA, Viral